A recent study confirms that the 100-year-old BCG vaccine does not protect against COVID-19, challenging early assumptions ...

Following the Bacillus Calmette-Guérin shortage, the first patient with bladder cancer has been dosed with recombinant ...

A live-attenuated tuberculosis (TB) vaccine candidate in development elicits a much more balanced and effective immune response compared to the existing vaccine used across much of the world, ...

AHMEDABAD: On National Vaccination Day, Gujarat shines with a 95.95% score in the SDG 3 Index, surpassing the national ...

In bladder cancer clinical trials in Europe, the recombinant BCG vaccine has demonstrated potent immunogenicity with CD8+ and CD4+ T cell stimulation and improved safety compared to earlier BCG ...

In bladder cancer clinical trials in Europe, the recombinant BCG vaccine has demonstrated potent immunogenicity with CD8+ and CD4+ T cell stimulation and improved safety compared to earlier BCG ...

People living with HIV are more than 14 times more likely to fall ill with TB disease than people without HIV.

U.S. Urology Partners is one of the first providers to offer patients ImmunityBio’s recombinant Bacillus Calmette-Guérin (rBCG) The FDA recently authorized ImmunityBio’s EAP for rBCG to address U.S.